Section Review: Cardiovascular & Renal: Blood substitutes in development

References

• FRATANTONI J: Demonstration of efficacy of a therapeu- •tic agent. In: Blood Substitutes: Physiological Basis of Effi-cacy. Winslow RM, Vandegriff RD, Intaglietta M (Eds.), Birkhauser, Boston (1995). An overview of the regulatory status of blood substitutes.
   Google Scholar
• WINSLOW RM: Hemoglobin-based red cell substitutes. •Johns Hopkins University Press, Baltimore, MD (1992). General background in blood substitutes including history of their development and an overview of the various types of products. 16. ••33.
   Google Scholar
• BIRO GP: Perfluorocarbon-based red blood cell substi-tutes. Transfus. Med. Rev. (1993) 7:84–95.
   PubMedGoogle Scholar
• BAKKER JC, BLEEKER WK: Blood substitutes based on modified hemoglobin. Vox. Sang. (1994) 67(Suppl.):139–142.
   Google Scholar
• ZUCK TF, RIESS JG: Current status of injectable oxygen •carriers. Crit. Rev. Clin, Lab. Sci. (1994) 31:295-324. Practical and critical view of how blood substitutes might fit into clinical practice and the problems facing their development.
   Google Scholar
• CHANG TM: Cross-linked hemoglobins being well into clinical trials, increasing research efforts are now on a second generation red blood cell substitute based on encapsulated hemoglobin. Art[ Cells Blood Substit. Im-mobil. Biotechnol. (1995) 23:257–262.
   PubMed Web of Science ®Google Scholar
• DIETZ NM, JOYNER MJ, WARNER MA: Blood substitutes:fluids, drugs, or miracle solutions? Anestb. Analg. (1996) 82:390–405.
   Google Scholar
• KUMAR R: Recombinant hemoglobins as blood substi-tutes: a biotechnology perspective. Proc. Soc. Exp. Biot Med. (1995) 208:150–158.
   PubMed Web of Science ®Google Scholar
• OGDEN JE, PARRY ES: The development of hemoglobinsolutions as red cell substitutes. Int. Anesthesiol. Clin. (1995) 33:115–129.
   PubMedGoogle Scholar
• SPENCE RIC: Perfiuorocarbons in the twenty-first cen- ▪tury: clinical applications as transfusion alternatives. Artif. Cells Blood Substit. Immobil. Biotechnol. (1995) 23:367-380. A clinical view of the applications for perfluorocarbon-based prod-ucts.
   Google Scholar
• WINSLOW RM: Blood substitutes: a moving target Nature •Medicine (1995) 1(11):1212–1215. A perspective on the targets and driving forces for product develop-ment in 1995.
   Google Scholar
• \WINSLOW RM, VANDEGRIFF KD, INTAGLIETTA M: In: Blood Substitutes: Physiological Basis of Efficacy. Birkhauser, Boston (1995).
   Google Scholar
• EATON JW: Haemoglobin-based blood substitutes: a dream-like trade of blood and guile? [Editorial com-ment]. J. Lab. Clin. Med. (1996) 127:416–417.
   PubMedGoogle Scholar
• BALLAJ, NATH KA, BALLA G et al.: Endothelial cell hemeoxygenase and ferritin induction in rat lung by hemo-globin in vivo. Am. J. Physiol. (Lung Cell Mol. Physiol. 12) (1995) 268:L321–L327.
   Google Scholar
• ELDRIDGE J, RUSSELL R, CHRISTENSON R et at: Liver function and morphology after resuscitation from se-vere hemorrhagic shock with hemoglobin solutions or autologous blood. Crit. Care Med. (1996) 24:663–671.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS E, CORTES A, GIILBERT N et al.: Hemoglobin-based blood substitutes and sepsis. Lancet (1995) 345:158-160. A controversial paper that raised the question of whether the use of haemoglobin-based products might potentiate infections.
   Google Scholar
• KACA W, ROTH RI, LEVIN J: Hemoglobin, a newly recog-nized lipopolysaccharide (LPS)-binding protein that enhances LPS biological activity. J. Biol. Chem. (1994) 269(49:25078–25084.
   PubMedGoogle Scholar
• HESS JR, MACDONALD VW, BRINKLEY WW: Systemic and spulmonary hypertension after resuscitation with cell- free hemoglobin. J. Appl. Physiol. (1993) 74:1769-1778. A realistic model of shock in the pig showing deleterious effects of unmodified haemoglobin in animals and hypertension in dehydrated animals.
   Google Scholar
• LEE R, NEYA K, SVIZZERO TA, VLAHAKES GJ: Limitations •of the efficacy of hemoglobin-based oxygen-carrying solutions. J. Appl. Physiol. (1995) 79:236-242. Systemic and pulmonary hypertension after use of a modified bovine haemoglobin could limit its clinical effectiveness.
   Google Scholar
• RIOUX F, DRAPEAU G, MARCEAU F: Recombinant human hemoglobin (rHb1.1) selectively inhibits vasorelaxa-tion elicited by nitric oxide donors in rabbit isolated aortic rings. J. Cardiovasr. Pharmacol. (1995) 25:587–594.
   Google Scholar
• ROLLWAGEN FM, GAFNEY WC, PACHECO ND et al.: Mul-tiple responses to administration of liposome-encapsu-lated hemoglobin (LEH): effects on hematopoiesis and serum IL-6 levels. Exp. Hematol. (1996) 24:429–436.
   PubMed Web of Science ®Google Scholar
• RABINOVICI R, NEVIILLE LF, RUDOLPH AS, FEUERSTEING: Hemoglobin-based oxygen-carrying resuscitation fluids [Editorial comment]. Crit. Care Med. (1995) 23:801–804.
   PubMed Web of Science ®Google Scholar
• RUDOLPH AS: Encapsulation of hemoglobin in •liposomes. In: Blood Substitutes: Physiological Basis of Effi-cacy. Winslow RM, Vandegriff KD, Intaglietta M (Eds.), Bidchauser, Boston (1995). Overview of current liposome technology as it relates to blood substitutes.
   Google Scholar
• SERVICE RF: Small spheres lead to big ideas [News]. Science (1995) 267:327–329.
   PubMed Web of Science ®Google Scholar
• GULATI A, SHARMA AC, SINGH G: Role of endothelin in the cardiovascular effects of diaspirin crosslinked and • stroma reduced hemoglobin. Crit. Care Med. (1996) 24:137-147. NO binding alone does not explain the hypertensive effect of haemoglobin.
   Google Scholar
• GULATI A, SHARMA AC, BURHOP ICE: Effect of stroma-free hemoglobin and diaspirin cross-linked hemoglo-bin on the regional circulation and systemic hemodynamics. Life Sci. (1994) 55:827–837.
   PubMed Web of Science ®Google Scholar
• SCHULTZ SC, POWELL CC, BURRIS DG et al.: The efficacy of diaspirin crosslinked hemoglobin solution resusci-tation in a model of uncontrolled haemorrhage. J. Trauma (1994) 37:408–412.
   PubMed Web of Science ®Google Scholar
• BOWES MP, BURHOP ICE, ZIVIN JA, ABRAHAM DJ: Dias-pirin cross-linked hemoglobin improves neurological outcome following reversible but not irreversible CNS ischemia in rabbits. Stroke (1994) 25:2253–2257.
   PubMed Web of Science ®Google Scholar
• HUGHES GS, Jr., YANCEY EP, ALBRECHT R et al.: Hemo-globin-based oxygen carrier preserves submaximal ex-ercise capacity in humans. Clin. Pharmacol. Tber. (1995) 58:434–443.
   Google Scholar
• HUGHES GS, Jr., FRANCOME SF, ANTAL EJ et al.: Hema-tologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J. Lab. Clin. Med. (1995) 126:444–451.
   Google Scholar
• GOULD SA, SEHGAL LR, SEEIGAL HL, MOSS GS: The development of hemoglobin solutions as red cell sub-stitutes: hemoglobin solutions. Transfus. Sci. (1995) 16:5–17.
   PubMedGoogle Scholar
• HOFFMAN SJ, LOOKER DL, ROEHRICH JM et al.: Expres-sion of fully functional tetrameric human hemoglobin In Eschericbta colt. Proc. Natl. Acad. Sci. USA (1990) 87:8521–8525.
   PubMed Web of Science ®Google Scholar
• LOOKER D, ABBOTT-BROWN D, COZART P eta: A human recombinant hemoglobin designed for use as a blood substitute. Nature (1992) 356:258-260. •• •• Pioneering work on production of 'di-a-haemoglobin' a genetically cross-linked haemoglobin in E. colt.
   Google Scholar
• MURRAY JA, LEDLOW A, LAUNSPACH J et al.: The effects ••of recombinant human hemoglobin on esophagealmotor functions in humans. Gastroenterology (1995) 109:1241-1248. Demonstration that GI 'side-effects' of haemoglobin are probably mediated by interference with oesophageal smooth muscle function.
   Google Scholar
• ANDRE M, NELSON T, MATTREY R: Physical and acousti-cal properties of perfh2orooctylbromide, an ultrasound contrast agent. Invest. Radio!. (1990) 25:983–987.
   PubMed Web of Science ®Google Scholar
• ROCKWELL S, KELLEY M, IRVIN CG et al.: Preclinical evaluation of Oxygent (TM) as an adjunct to radiother-apy. Biomater. Artif. Cells Immobil. Biotechnol. (1992) 20:883–893.
   PubMed Web of Science ®Google Scholar
• FLAIM SF, HAZARD DR, HOGAN J, PETERS RM: Charac- •terization and mechanism of side-effects of Imagent BP (highly concentrated fluorocarbon emulsion) in swine. Invest. Radio!. (1991) 26(Suppl.):S122-S124; S125-S128 (dis-cussion). Demonstration that the 'flu-like' symptoms observed with perfluoro-carbon-based products are due to cytokine release.
   Google Scholar
• BRAUN RD, LINSENMEIER RA, GOLDSTICK TK: New per- •fluorocarbon emulsion improves tissue oxygenation in cat retina. J. Appl. Physiol. (1992) 72:1960-1968. Provocative observation that tissue PO rises after administration of small amounts of perfluorocarbon-based products.
   Google Scholar
• HOGAN MC, KURDAK SS, RICHARDSON RS, WAGNER PD: • Partial substitution of red blood cells with free hemo-globin solution does not improve maximal 02 uptake of working in situ dog muscle. Adv. Exp. Med. Biol. (1994) 361:375–378.
   PubMedGoogle Scholar
• Demonstration that cell-free haemoglobin can support VO2m.a., as well as red blood cells. O.CURTIS SE, PEEK J: Intratracheal administration of per- ••flubron improves gas exchange and lung mechanics after acute lung injury. J. Clin. Res. (1992) 40:799A. An early report of the use of perfluorocarbon in partial liquid ventilation.
   Google Scholar
• KAUFMAN RJ: Clinical development of perfluorocarbon-based emulsions as red cell substitutes. In: Blood Substi-tutes: Physiological Basis of Efficacy. Winslow RM, Vandegriff KD, Intaglietta M (Eds.), Birkhauser, Boston (1995).
   Google Scholar
• BLAUTH CI, ARNOLD JV, SCHULENBERG WE, MCCARTNEY AC, TAYLOR KM: Cerebral microembolism during car-diopulmonary bypass. Retinal microvascular studies in vivo with fluorescein angiography. J. Thorac. Cardiovasc. Stag. (1988) 95:668–676.
   PubMed Web of Science ®Google Scholar
• BLAUTH C, SMITH P, NEWMAN S et al.: Retinal microem-bolism and neuropsychological deficit following clini-cal cardiopulmonary bypass: comparison of a membrane and a bubble oxygenator. A preliminary communication. Eur. J. Cardiothorac. Surg. (1989) 3:135-138; 139 (discussion).
   Google Scholar
• SPIESS BD, MCCARTHY RJ, TUMAN KJ etal.: Treatment of decompression sickness with a perfluorocarbon emul-sion (FC-43). Undersea Biomed. Res. (1988) 15:31–37.
   Google Scholar
• BLAUTH C, ARNOLD J, KOHNER EM, TAYLOR KM: Retinal microembolism during cardiopulmonary bypass dem-onstrated by fluorescein angiography. Lancet (1986) 2:837–839.
   PubMed Web of Science ®Google Scholar
• TAYLOR KM, ARNOLD JV, FLEMING J et al.: Cerebral protection during C.PB using perfluorocarbon: a pre-liminary report. 2nd Int. Conf. Brain & Cardiac Surgery (1992).
   Google Scholar
• ANON: Novel stroke treatment threatens to blow gluta-mate antagonists out of the water [News item]. Emerging Pharmaceuticals (1995) 4:2–3.
   Google Scholar
• BURKARD ME, VAN LIEW HD. Oxygen transport to tissue by persistent bubbles: theory and simulations. J. Appl. Physiol. (1994) 77(6):2874–2878.
   PubMed Web of Science ®Google Scholar
• TOMASULO P: Transfusion alternatives: impact on ••blood banking worldwide. In: Blood Substitutes: Physi-ological Basis of Efficacy. Winslow RM, Vandegriff KD, Intaglietta M (Eds.), Birkhauser, Boston (1995). A global view of the need and potential market for blood substitutes.
   Google Scholar
• HUANG NS, HELLUMS JO: A theoretical model for gas transport and add/base regulation by blood flowing in microvessels. Microvasc. Res. (1994) 48:364–388.
   PubMed Web of Science ®Google Scholar
• HOGAN MC, WIILLFORD DC, KEIPERT PE, FAITHFULL NS, •WAGNER PD: Increased plasma 02 solubRity improves 02 uptake of in situ dog muscle working maximally. J. Appl. Physiol. (1992) 73:2470-2475. Failure of perfluorocarbon emulsions to show expected facilitated diffusion.
   Google Scholar
• INTAGLIETTA M, JOHNSON PC, WINSLOW RM: Microvas- •cular and tissue oxygen distribution. An invited review. Cardiovasc. Res. (1996). In press. A new view of how 02 is transported in the microcirculation. Robert M Winslow, M.D., Department of Medicine, Division of Hematology & Oncology, University of California, San Diego, Vet-erans Affairs Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161, USA (Tel: 619 552 8585 extn. 7625; Fax: 619 552 7578).
   Google Scholar